Leerink Swann maintains a rosy Outperform rating on Idenix Pharmaceuticals (IDIX +0.7%) on the...

|About: Idenix Pharmaceuticals, Inc. (IDIX)|By:, SA News Editor

Leerink Swann maintains a rosy Outperform rating on Idenix Pharmaceuticals (IDIX +0.7%) on the strength of its conviction that the company will eventually sign a licensing deal with Gilead Sciences that ends a patent fight and provides a revenue boost for the company.